Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their ...

"Sana exists to build the UI for AI and bring superintelligence to work," said Joel Hellermark, CEO, Sana. "Joining Workday ...

Announced increased focus on type 1 diabetes and in vivo CAR T programsRegulatory interactions increase confidence in moving forward with GMP ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the TD Cowen ...

Sana Biotechnology, Inc. ( (SANA) ) has released its Q3 earnings. Here is a breakdown of the information Sana Biotechnology, Inc. presented to its investors.Meet Your ETF AI Analyst Discover how ...

Sana Biotechnology Inc. SANA) on Thursday reported a loss of $42.2 million in its third quarter. On a per-share basis, the Seattle-based company said it had a loss of 16 cents.

Pre-earnings options volume in Sana Biotechnology (SANA) is normal with calls leading puts 27:1. Implied volatility suggests the market is ...

Sana Biotechnology is restructuring and narrowing its focus for the second time in less than a year. With its stock in the doldrums, the cell engineering biotech is pulling back from its in vivo ...